Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue decreased due to the drug price revision, generic drug entry for Desalex, and the decline in overseas income related to gatifloxacin, among other factors. Operating profit was affected by the decline in revenue, while selling, general and administrative expenses decreased due to the absence of the upfront fee recognized in the same period of the previous year. Net income reflected a ¥2,528 million loss on transfer of business related to the transfer of the generic drugs business.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥57,489 million (YoY -2.1%) |
| Operating profit | ¥306 million (YoY -77.6%) |
| Ordinary income | ¥689 million (YoY -56.4%) |
| Profit attributable to owners of the parent | ¥-1,566 million |
| Net income per share | -¥27.26 |
| Equity ratio | End of the current fiscal period 73.9 / End of previous period 72.9 |
| Total assets | ¥186,819 million |
| Net assets | ¥138,057 million |
| Cash flows from operating activities | ¥11,995 million |
| Cash flows from investing activities | ¥-501 million |
| Cash flows from financing activities | ¥-2,353 million |
| Cash and cash equivalents at end of period | ¥20,942 million |
| Full-year earnings forecast | Net Sales ¥121,800 million (YoY -3.5%) / Operating profit ¥-4,900 million / Ordinary income ¥-4,600 million / Net income ¥-5,100 million |
| Revision to Earnings Forecast | Net Sales ¥121,800 million → ¥121,800 million / Operating profit ¥2,000 million → ¥-4,900 million / Ordinary income ¥2,300 million → ¥-4,600 million / Profit attributable to owners of the parent ¥1,500 million → ¥-5,100 million |
| Annual Dividend Forecast | ¥57 → ¥25 |
| Depreciation and amortization | ¥2,299 million |
| Impairment loss | ¥1,934 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Subsidy Income ¥100 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥7 million, Loss on sale of investment securities ¥1 million, Impairment loss on investment securities ¥152 million, Loss on transfer of business ¥2,528 million |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Material subsequent events | The Company entered into a business separation agreement to transfer the generic drugs business to 株式会社医薬品共創機構, with the business separation scheduled for 1 April 2027. The Company also entered into a license agreement with Edesa Biotech, Inc. for the development and sale in Japan of EB05, a drug candidate for the treatment of ARDS, and will pay an upfront fee of US$12 million. |
| Supplementary financial results materials | Available |
| Availability of Financial Results Briefing | Yes (for analysts, institutional investors and others) |
| Issued Shares at Period-End | 59,945,641 |
| Treasury Shares at Period-End | 2,353,573 |
| Factors Behind Changes in Business Performance | Revenue decreased due to the drug price revision, generic drug entry for Desalex, and the decline in overseas income related to gatifloxacin, among other factors. Operating profit was affected by the decline in revenue, while selling, general and administrative expenses decreased due to the absence of the upfront fee recognized in the same period of the previous year. Net income reflected a ¥2,528 million loss on transfer of business related to the transfer of the generic drugs business. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to the decline in revenue, the Company incorporated into its operating profit and ordinary profit forecasts the upfront fee and other payments associated with the license agreement with Edesa Biotech, Inc. The forecast for net income attributable to owners of the parent reflects the loss on transfer of business related to the transfer of the generic drugs business. The interim net loss resulted from the recognition of a ¥2,528 million loss on transfer of business as an extraordinary loss.